PK of Efavirenz & Lopinavir Nano-formulations in Healthy Volunteers
NCT ID: NCT02631473
Last Updated: 2016-12-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
SUSPENDED
PHASE1
50 participants
INTERVENTIONAL
2015-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Primary
* To investigate the pharmacokinetics of a new pharmaceutical formulation of efavirenz (NANO-efavirenz) in HIV negative healthy volunteers after single dose and a steady-state.
* To investigate the pharmacokinetics of a new pharmaceutical formulation of lopinavir (NANO-lopinavir) in HIV negative healthy volunteers
Secondary
* To investigate the safety and tolerability of NANO-efavirenz and NANO-lopinavir in HIV negative healthy volunteers
* To assess the bioequivalence of a selected single-dose of NANO-efavirenz to a single dose 600mg of efavirenz as Sustiva®
* To investigate the association between genetic polymorphisms in drug disposition genes and drug exposure
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1st Stage-Group A
1. Day 1: 50 mg NANO-efavirenz single dose
2. Days 4-21: 50 mg NANO-efavirenz OD (once daily)
50mg NANO-efavirenz
OD
1st Stage-Group B
1. Days 1-7: 400mg NANO-lopinavir BID (twice daily)
2. Days 8-21: Wash-out period
3. Days: 22-28: 200mg NANO-lopinavir BID plus 100mg Ritonavir (Norvir) BID
400mg NANO-Lopinavir
BID
200mg NANO-Lopinavir
BID
100mg Ritonavir
BID
2nd Stage-Group A-Group 1-Dose level 1
1. 21 Days: 300mg NANO-efavirenz OD
2. 4 weeks: Wash-out period
3. 21 days: 600mg Sustiva OD
300mg NANO-Efavirenz
OD
600mg Sustiva
OD
2nd Stage-Group A-Group 2-Dose level 2
1. 21 Days: 200mg NANO-efavirenz OD
2. 4 weeks: Wash-out period
3. 21 days: 400mg Sustiva OD
200mg NANO-Efavirenz
OD
400mg Sustiva
2nd Stage-Group B-Arm 1
1. 7 days: Kaletra® (lopinavir400mg/ritonavir100mg) BD
2. 2 weeks: Wash-out period
3. 7 days: NANO-lopinavir (200mg +/- ritonavir®)
Kaletra® (lopinavir 400mg/ritonavir 100mg)
BID
+/- 200mg NANO-Lopinavir
BID
+/- 200mg ritonavir NORVIR
BID
2nd Stage-Group B-Arm 2
1. 7 days: NANO-lopinavir (200mg +/- ritonavir Norvir)
2. 2 weeks: Wash-out period
3. 7 days: Kaletra® (lopinavir400mg/ritonavir100mg) BD
Kaletra® (lopinavir 400mg/ritonavir 100mg)
BID
+/- 200mg NANO-Lopinavir
BID
+/- 200mg ritonavir NORVIR
BID
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
50mg NANO-efavirenz
OD
400mg NANO-Lopinavir
BID
200mg NANO-Lopinavir
BID
100mg Ritonavir
BID
300mg NANO-Efavirenz
OD
600mg Sustiva
OD
200mg NANO-Efavirenz
OD
Kaletra® (lopinavir 400mg/ritonavir 100mg)
BID
+/- 200mg NANO-Lopinavir
BID
+/- 200mg ritonavir NORVIR
BID
400mg Sustiva
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Male or non-pregnant, non-lactating females
3. Between 18 to 65 years, inclusive
4. Body Mass Index (BMI) of 18 to 30 kg/m2, inclusive
5. Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for a period of at least 12 weeks after the study
A female may be eligible to enter and participate in the study if she:
1. is of non-child-bearing potential defined as either post-menopausal (12 months of spontaneous amenorrhea and ≥ 45 years of age) or physically incapable of becoming pregnant with documented tubal ligation, hysterectomy or bilateral oophorectomy or,
2. is of child-bearing potential with a negative pregnancy test at both Screening and Day 1 and agrees to use one of the following methods of contraception to avoid pregnancy:
* Complete abstinence from penile-vaginal intercourse from 2 weeks prior to administration of IP, throughout the study, and for at least 2 weeks after discontinuation of all study medications;
* Double barrier method (male condom/spermicide, male condom/diaphragm, diaphragm/spermicide);
* Any intrauterine device (IUD) with published data showing that the expected failure rate is \<1% per year (not all IUDs meet this criterion, see protocol appendix 7 for an example listing of approved IUDs);
* Condom and depot medroxyprogesterone acetate ( DMPA) injections
* Male partner sterilization confirmed prior to the female subject's entry into the study, and this male is the sole partner for that subject;
* Any other method with published data showing that the expected failure rate is \<1% per year.
* Any contraception method must be used consistently, in accordance with the approved product label and for at least 2 weeks after discontinuation of IP.
6. Willing to consent to their personal details being entered onto the TOPS database
7. Willing to provide proof of identity by photographic ID at screen and any subsequent visit
8. Registered with a GP in the UK
Exclusion Criteria
2. Prolongation of ECG intervals: PR \> 200 msec or QTcF \> 450 msec.
3. Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, ECG or clinical laboratory determinations.
4. Liver transaminase (ALT or AST \> 1.25 x the upper limit of the normal range)
5. Significant psychiatric history (including severe depression) or history of seizures.
6. Positive blood screen for either hepatitis B surface antigen or hepatitis C antibody
7. Positive blood screen for HIV-1 and/or 2 antibodies
8. Current or recent (within 3 months) gastrointestinal disease
9. Clinically relevant alcohol or drug use (positive urine drug screen) or history of alcohol or drug use considered by the Investigator to be sufficient to hinder adherence to treatment, follow-up procedures or evaluation of adverse events. Smoking is permitted, but tobacco intake should remain consistent throughout the study
10. Known cardiac disease history of any family history of sudden cardiac death.
11. Exposure to any investigational drug or placebo within 3 months of first dose of study drug
12. Use of any other drugs (unless approved by the Investigator), including over-the-counter medications and herbal preparations, within two weeks prior to first dose of study drug, unless approved/prescribed by the Principal Investigator as known not to interact with study drugs.
13. Females of childbearing potential without the use of effective non-hormonal birth control methods, or not willing to continue practising these birth control methods for at least 12 weeks after the end of the treatment period
14. Previous allergy to any of the constituents of the pharmaceuticals administered in this trial
15. Rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucosegalactose malabsorption
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Liverpool
OTHER
St Stephens Aids Trust
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Marta Boffito
Role: PRINCIPAL_INVESTIGATOR
Chelsea & Westminster Hospital
Steve Rannard
Role: STUDY_DIRECTOR
University of Liverpool
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
St Stephen's Centre
London, London, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SSAT 055
Identifier Type: -
Identifier Source: org_study_id